Adding encorafenib and cetuximab to chemotherapy backbone also prolonged overall survival ...

The study, "BRAF oncogenic mutants evade autoinhibition through a common mechanism," published in Science, was conducted by co-first authors Hugo Lavoie, Ting Jin and Driss Lajoie, all of IRIC, in ...

SAN FRANCISCO -- First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant metastatic colorectal cancer (mCRC), according to the BREAKWATER ...

Serial monitoring of circulating tumor DNA as a marker of response to immune checkpoint blockade in MSI-H gastrointestinal tumors. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal ...

A review article led by researchers from the B·ARGO group at the Germans Trias i Pujol Research Institute (IGTP) and from the Medical Oncology Department of the Catalan Institute of Oncology (ICO) in ...

NEW YORK, Sept 14 (Reuters) - Pfizer (PFE.N), opens new tab is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the ...

Metastatic colorectal cancer (mCRC) harbouring BRAF mutations, most frequently the V600E variant, accounts for approximately 8–12% of cases and is associated with aggressive clinical behaviour and ...

Using AI, we identified publications that likely reported a testing or mutation rate, filtered publications for cancer type, and identified sentences that likely reported rates. Rates and covariates ...

The BRAF mutation in lung cancer means that your cancer started due to a change in the BRAF gene. It may affect your treatment options and outlook. The BRAF gene is partially responsible for cell ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...